Department of General Surgery, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, 3 East Qingchun Road, Hangzhou, 310016, Zhejiang, China.
Surg Endosc. 2021 Jul;35(7):3267-3278. doi: 10.1007/s00464-020-07763-6. Epub 2020 Jul 6.
The presence of clinically significant portal hypertension (CSPH) remains a relative contraindication to liver resection for patients with resectable hepatocellular carcinoma (HCC). The goal of this study was to explore whether a laparoscopic approach could extend the indications for hepatectomy to patients with PH.
Patients who underwent laparoscopic liver resection (LLR) from February 2016 to September 2019 performed by a single medical team were included in this study. We analyzed the surgical and oncological outcomes between groups with and without CSPH before and after propensity score matching (PSM).
We enrolled 156 patients divided into two groups according to the presence (CSPH, n = 26) or absence (non-CSPH, n = 130) of CSPH. CSPH group was associated with more clinical signs of liver dysfunction (p < 0.05). After PSM (n = 48 patients), the CSPH group tended to have a longer postoperative hospital stay (p = 0.054); however, there was no difference in operation time (p = 0.329), blood loss volume (p = 0.392), transfusion rates (p = 0.701), rate of conversion to open surgery (p = 0.666), surgical margin (p = 0.306), surgical mortality (n = 0), or comprehensive complication index (p = 0.844) between the two groups. The median follow-up time for the entire cohort was 19.6 months (range 0.2-40.6 months). The 3-year overall survival rate was 62.9% in the CSPH group and 84.3% in the non-CSPH group (p = 0.1090), and results were similar after PSM (p = 0.5734).
LLR is safe and feasible for HCC with PH. The introduction of minimally invasive surgery, represented by LLR, can appropriately expand the indications for hepatectomy.
对于可切除肝细胞癌(HCC)患者,存在临床显著门静脉高压症(CSPH)仍然是肝切除术的相对禁忌症。本研究的目的是探讨腹腔镜方法是否可以将肝切除术的适应证扩展到 PH 患者。
本研究纳入了 2016 年 2 月至 2019 年 9 月期间由同一医疗团队进行腹腔镜肝切除术(LLR)的患者。我们分析了 CSPH 组(n=26)和非 CSPH 组(n=130)患者在倾向评分匹配(PSM)前后的手术和肿瘤学结果。
我们根据是否存在 CSPH(CSPH 组,n=26)将 156 例患者分为两组,将其分为 CSPH 组和非 CSPH 组。CSPH 组的肝功能不全临床征象更为明显(p<0.05)。PSM 后(n=48 例),CSPH 组的术后住院时间较长(p=0.054);但手术时间(p=0.329)、失血量(p=0.392)、输血率(p=0.701)、中转开腹率(p=0.666)、切缘(p=0.306)、手术死亡率(n=0)和综合并发症指数(p=0.844)无差异。整个队列的中位随访时间为 19.6 个月(范围 0.2-40.6 个月)。CSPH 组的 3 年总生存率为 62.9%,非 CSPH 组为 84.3%(p=0.1090),PSM 后结果相似(p=0.5734)。
对于 PH 的 HCC,LLR 是安全可行的。以 LLR 为代表的微创外科的引入,可以适当扩大肝切除术的适应证。